Nisa Investment Advisors LLC Lowers Holdings in Johnson & Johnson (NYSE:JNJ)

Nisa Investment Advisors LLC cut its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 732,785 shares of the company's stock after selling 46,276 shares during the period. Johnson & Johnson accounts for about 0.6% of Nisa Investment Advisors LLC's investment portfolio, making the stock its 21st biggest position. Nisa Investment Advisors LLC's holdings in Johnson & Johnson were worth $121,525,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. WealthTrak Capital Management LLC acquired a new position in Johnson & Johnson during the fourth quarter worth $26,000. Mountain Hill Investment Partners Corp. acquired a new stake in shares of Johnson & Johnson during the 4th quarter worth $29,000. Conquis Financial LLC bought a new stake in Johnson & Johnson during the fourth quarter worth $33,000. Bernard Wealth Management Corp. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the 4th quarter valued at $38,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analyst Ratings Changes

Several research analysts have commented on JNJ shares. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, June 5th. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a report on Thursday. Bank of America decreased their price target on shares of Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a research note on Thursday, April 10th. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Finally, Barclays decreased their price objective on shares of Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a research note on Thursday, April 17th. Eleven investment analysts have rated the stock with a hold rating, seven have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $171.00.

Johnson & Johnson Price Performance

NYSE JNJ traded down $0.82 during trading hours on Friday, reaching $156.87. 7,866,488 shares of the stock traded hands, compared to its average volume of 8,066,975. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.26 and a quick ratio of 1.03. The stock has a 50 day simple moving average of $153.73 and a two-hundred day simple moving average of $154.35. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market cap of $377.44 billion, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 2.15 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The business had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. On average, analysts predict that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's payout ratio is currently 57.84%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.